K040385

APR - 7 2004

Section 11

510(k) Summary of Safety and Effectiveness

SUBMITTER INFORMATION: 1.

Submitter's Name:

Address:

Quest Medical, Inc.

One Allentown Parkway

Allen, Texas 75002 972-390-9800

Telephone:

Fax Number.

972-390-2881

Contact Person:

Kathryn J. Thompson

Date Prepared:

1 April 2004

DEVICE INFORMATION: 2.

Proprietary Name:

Common/Usual Names:

Classification:

Multiport® Manifold I.V. Set with Swabable Valves

Intravascular Administration Sets, I.V. Sets

Class II, 21 CFR 880,5440

PREDICATE DEVICE:

Baxter Continu-Flo Solution Set, 2C8930, K003225

DEVICE DESCRIPTION: 3.

Sterile single use, non-pyrogenic intravenous fluid administration set: 85 in. (216 cm) long, multiport IV manifold with integrated back check valves, pre-attached needleless

injection sites, drip chamber, roller clamps.

INTENDED USE: 4.

For administration of intravenous fluids to a patient's vascular system utilizing needleless components and an I.V. manifold for multiple simultaneous intravenous therapy via

gravity, syringe, or infusion pump.

SUMMARY OF TECHNOLOGICAL CHARACTERISTICS OF NEW DEVICE TO 5. PREDICATE DEVICE:

The technological characteristics of the Multiport IV Set do not differ significantly from the currently marketed Baxter Continu-Flo set. The devices use the same fundamental scientific technology and have the same intended use.

NON-CLINICAL TEST CONCLUSIONS: 6.

> The results of laboratory testing (design verification) using the FDA guidance for Intravascular Administration Sets demonstrate acceptable performance of the device.



APR - 7 2004

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Quest Medical, Incorporated C/O Mr. Jeremi Peck Responsible Third Party Official Underwriters Laboratories Incorporated 333 Pfingsten Road Northbrook, Illinois 60062

Re: K040385

Trade/Device Name: Multiport® Manifold I.V. Set 3 with Swabable Valves

Regulation Number: 880.5440

Regulation Name: Intravascular Administration Set

Regulatory Class: II Product Code: FPA Dated: March 16, 2004 Received: March 23, 2004

Dear Mr. Peck:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-5618. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

K040385

SECTION 5 INDICATIONS FOR USE STATEMENT

	510(k) Number:	
	Device Name:	Multiport® Manifold I.V. Set with Swabable Valves
	Indications for Use:	For administration of intravenous fluids to a patient's vascular system utilizing needleless components and an I.V. manifold for multiple simultaneous intravenous therapy via gravity, syringe, or infusion pump.
I I —	>	The needleless safety feature may aid in the prevention of needlestick injury.
	(Please do not write below this line—continue on another page if needed)	
	CONCURRENCE	OF CDRH, OFFICE OF DEVICE EVALUATION (ODE)
	Prescription Use <u>√</u> (Per 21 CFR 801.109)	OR Over-The-Counter Use
	(Division Sign-Off) Division of Anesthesiology, General Hospital, Infection Control, Dental Devices	
	510(k) t	Number: K 04 03 85